Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study).

Saved in:
Bibliographic Details
Title: Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study).
Authors: Molina-Cerrillo J; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., Roviello G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy., Bourlon MT; Department of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.; Universidad Panamericana, Escuela de Medicina, Mexico City, Mexico., Studentova H; Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic., Fiala O; Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Cerbone L; Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy., Kucharz J; Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Ansari J; Medical Oncology, Tawam Hospital, Al Ain, UAE., Zeppellini A; Medical Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Taha T; Royal Marsden NHS Foundation Trust, London, UK., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy., Ürün Y; Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Türkiye., Scagliarini S; Department of Medical Oncology, AORN 'A. Cardarelli', Naples, Italy., Li H; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood, Ksansas, USA., Sunela K; Department of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Park SH; Department of Hematology and Oncology, Sungkyunkwan University Samsung Medical Center, Seoul, South Korea., Rizzo M; Medical Oncology Unit, Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari, Bari, Italy., Zgura A; Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania., Chiari R; Azienda Ospedaliera 'Ospedali Riuniti Marche Nord', Pesaro y Urbino, Italy., Seront E; Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium., Catalano M; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy., Ghosn M; Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon., Filosa A; Anatomic Pathology, Department of Biomedical Sciences and Public Health, University 'Politecnica delle Marche', Ancona, Italy., Soares A; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Oncology Unit, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Monteiro FSM; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Oncology and Hematology Department, Hospital Sírio Libanês, Brasília, Brazil., Grande E; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Porta C; Chair of Oncology, Interdisciplinary Department of Medicine, University of Bari 'Aldo Moro', Bari, Italy., Bracarda S; Medical Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy., Santoni M; Medical Oncology Unit, Macerata Hospital, Macerata, Italy.
Source: International journal of cancer [Int J Cancer] 2026 Mar 01; Vol. 158 (5), pp. 1396-1405. Date of Electronic Publication: 2025 Nov 04.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-0215
DOI:10.1002/ijc.70228